The FAB and WHO classification in AML: An analysis from the application in 150 cases

HAEMA

Volumn 8, Issue 3, 2005, Pages 465-472

  Goumakou, Eleni ^a,b   Papadhimitriou, Stephanos I ^a   Kritikou Griva, Elpiniki ^a   Marinakis, Theodoros ^a   Paterakis, George ^a   Davea, Ageliki ^a   Leivada, Anastasia ^a   Galanopoulos, Athanasios ^a   Anagnostopoulos, Nikolaos I ^a  

^a KAT HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Acute myeloid leukemia; Classification; Dysplasia; FAB; Prognosis; WHO

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; CD14 ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD36 ANTIGEN; CD56 ANTIGEN; CD61 ANTIGEN; CD64 ANTIGEN; CD68 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; FIBRINOGEN RECEPTOR; GLYCOPHORIN A; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CYTOCHEMISTRY; CYTOGENETICS; DISEASE CLASSIFICATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; PROGNOSIS; WORLD HEALTH ORGANIZATION;

EID: 23044480134     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997 J Clin Oncol 1999; 17: 3835-3849.
2. Jaffe ES, Harris NL, Stein H et al. Pathology and Genetics. Tumors of Hemopoietic and Lymphoid Tissues. World Health Organization Classification of Tumors, 2001.
3. Preiss BS, Kerndrup GB, Schmidt KG et al. Cytogenetic findings in adult de novo acute myeloid leukemia. A population-based study of 303/337 patients. Br J Haematol 2003; 123: 219-234.
4. Arber DA, Stein AS, Carter NH et al. Prognostic impact of acute myeloid leukemia classification. Am J Clin Path 2003; 119: 672-680.
5. Bene MC, Gastoldi G, Knapp W et al. Proposals for the immunological classification of acute leukemias. Europian Group for the Immunological Characterization of Leukemias (EGIL) Leukemia 1995; 9: 1783-1786.
6. Bennett JM, Catovsky D, Daniel MT. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 620-629.
7. Byrd JC, Mrozek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
8. Caneda K, Kojima K, Takeuchi M et al. Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome? Eur J Haematol 2002; 69: 165-170.
9. Latger-Cannard V, Buisine J, Fenneteau O et al. Dysgranulopoiesis, low blast count and t(8;21): an unusual presentantion of t(8;21) AML according to the WHO classification: a pediatric experience. Leuk Res 25; 2001: 1023-1024.
10. th Greek Haematology Congress, Patras 2002.
11. Sainty D, Liso V, Cantu-Ranjnoldi A et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood 2000; 96: 1287-1296.
12. Haferlach T, Schoch C, Loffler H et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003; 21: 256-265.
13. Kahl C, Florschutz A, Muller G et al. Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia. Ann Hematol 1997; 75: 91-94.
14. Taguchi J, Miyazaki Y, Yoshida S et al. Allogeneic bone marrow transplantation improves the outcome of de novo AML with trilineage dysplasia (AML-TLD). Leukemia 2000; 14: 1861-1866.
15. Tamura S, Takemoto Y, Hashimoto-Tamaoki T et al. Cytogenetic analysis of de novo acute myeloid leukemia with trilineage myelodysplasia in comparison with myelodysplastic syndrome evolving to acute myeloid leukemia. Int J Oncol 1998; 12: 1259-1262.
16. Miyazaki Y, Kuriyama K, Miyawaki S et al. Cytogenetic heterogeneity of acute myeloid leukemia (AML) with trilineage dysplasia: Japan Adult Leukemia Study Group-AML 92 study. Br J Haematol 2003; 120: 56-62.
17. Sun X, Medeiros LJ, Lu D, Rassidakis GZ, Buesco-Ramos C. Dysplasia and high proliferation rate are common in acute myeloid leukemia with inv(16)(p13q22). Am J Clin Path 2003; 120: 236-245.
18. Schoch C, Haferlach T, Haase D et al. Patients with de novo acute leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001; 112: 118-126.
19. Rowe JM. Therapy of secondary leukemia. Leukemia 2002; 16: 748-750.